Last updated: 15 June 2023 at 5:37pm EST

Fred Kurland Net Worth




The estimated Net Worth of Fred Kurland is at least 226 千$ dollars as of 4 May 2023. Mr Kurland owns over 4,000 units of Aridis Pharmaceuticals Inc stock worth over 4$ and over the last 20 years he sold ARDS stock worth over 0$. In addition, he makes 226,188$ as Consultant at Aridis Pharmaceuticals Inc.

Mr Kurland ARDS stock SEC Form 4 insiders trading

Mr has made over 12 trades of the Aridis Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of ARDS stock worth 4$ on 4 May 2023.

The largest trade he's ever made was exercising 29,938 units of Aridis Pharmaceuticals Inc stock on 6 April 2015 worth over 30$. On average, Mr trades about 6,004 units every 232 days since 2004. As of 4 May 2023 he still owns at least 4,000 units of Aridis Pharmaceuticals Inc stock.

You can see the complete history of Mr Kurland stock trades at the bottom of the page.





Mr. Fred Kurland biography

Fred Kurland is the Consultant at Aridis Pharmaceuticals Inc.

What is the salary of Mr Kurland?

As the Consultant of Aridis Pharmaceuticals Inc, the total compensation of Mr Kurland at Aridis Pharmaceuticals Inc is 226,188$. There are 1 executives at Aridis Pharmaceuticals Inc getting paid more, with Dr. Vu L. Truong having the highest compensation of 566,125$.



How old is Mr Kurland?

Mr Kurland is 69, he's been the Consultant of Aridis Pharmaceuticals Inc since . There are 2 older and 3 younger executives at Aridis Pharmaceuticals Inc. The oldest executive at Aridis Pharmaceuticals Inc is Dr. Eric J. Patzer, 71, who is the Exec. Chairman.

What's Mr Kurland's mailing address?

Fred's mailing address filed with the SEC is C/O ARIDIS PHARMACEUTICALS, INC., 983 UNIVERSITY AVENUE, BLDG. B, LOS GATOS, CA, 95032.

Insiders trading at Aridis Pharmaceuticals Inc

Over the last 6 years, insiders at Aridis Pharmaceuticals Inc have traded over 0$ worth of Aridis Pharmaceuticals Inc stock and bought 1,445,847 units worth 181,502$ . The most active insiders traders include Vu TruongEric PatzerFred Kurland. On average, Aridis Pharmaceuticals Inc executives and independent directors trade stock every 89 days with the average trade being worth of 125$. The most recent stock trade was executed by Eric Patzer on 24 June 2024, trading 714,286 units of ARDS stock currently worth 50,000$.



What does Aridis Pharmaceuticals Inc do?

aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.



What does Aridis Pharmaceuticals Inc's logo look like?

Aridis Pharmaceuticals Inc logo

Complete history of Mr Kurland stock trades at Corcept Therapeutics Inc、XOMA Royalty、Aridis Pharmaceuticals Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
4 May 2023 Fred Kurland
CFO
オプション行使 4,000 0.18$ 720$
4 May 2023
4,000
6 Apr 2015 Fred Kurland
VPファイナンス
オプション行使 29,938 70.00$ 2,095,660$
6 Apr 2015
75,461
18 Mar 2015 Fred Kurland
VPファイナンス
オプション行使 10,875 79.60$ 865,650$
18 Mar 2015
80,798
13 Nov 2014 Fred Kurland
VPファイナンス
オプション行使 22,596 79.40$ 1,794,122$
13 Nov 2014
93,859
14 Aug 2014 Fred Kurland
VPファイナンス
オプション行使 19,064 86.40$ 1,647,130$
14 Aug 2014
81,664
18 Mar 2014 Fred Kurland
VPファイナンス
オプション行使 10,875 128.00$ 1,392,000$
18 Mar 2014
68,515
13 Nov 2013 Fred Kurland
VPファイナンス
オプション行使 22,596 80.80$ 1,825,757$
13 Nov 2013
34,416
14 Aug 2013 Fred Kurland
VPファイナンス
オプション行使 19,064 79.80$ 1,521,307$
14 Aug 2013
32,549
13 Nov 2012 Fred Kurland
VPファイナンス
オプション行使 22,596 55.20$ 1,247,299$
13 Nov 2012
22,596
25 Mar 2011 Fred Kurland
VPファイナンス
購入する 5,000 3.26$ 16,300$
25 Mar 2011
5,000
20 Dec 2005 Fred Kurland
最高財務責任者
購入する 2,500 4.15$ 10,375$
20 Dec 2005
7,500
29 Nov 2004 Fred Kurland
最高財務責任者
購入する 5,000 4.52$ 22,600$
29 Nov 2004
5,000


Aridis Pharmaceuticals Inc executives and stock owners

Aridis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: